Bromide

Bromide

SCHEMBL102597

Br.PC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 4/20 0.45
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
ALOX15 P16050 1/20 0.36
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
PTPN1 P18031 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL28303509 0.97 KCNN4 (0.43) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Bromide SCHEMBL28212776 0.97 KCNN4 (0.43) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Bromide SCHEMBL28212775 0.97 KCNN4 (0.43) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Bromide SCHEMBL27870891 0.97 KCNN4 (0.43) KCNN4ALDH1A1TSHRMAPK1CYP1A2
SCHEMBL416260 0.97 KCNN4 (0.47) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Hydrochloric Acid SCHEMBL28904471 0.93 KCNN4 (0.45) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Hydrochloric Acid SCHEMBL28904470 0.93 KCNN4 (0.45) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Iodide SCHEMBL114296 0.93 KCNN4 (0.45) KCNN4ALDH1A1TSHRMAPK1CYP1A2
SCHEMBL30581193 0.93 KCNN4 (0.45) KCNN4ALDH1A1TSHRMAPK1CYP1A2
Hydrochloric Acid SCHEMBL113885 0.93 KCNN4 (0.45) KCNN4ALDH1A1TSHRMAPK1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079956-A Preparation method of heterocyclic compound 2026-05-26 CN claimed
CN-119978028-A Preparation method of high-temperature-resistant phosphorus salt antistatic agent 达创新材料科技(山东)有限公司 2025-05-13 CN claimed
CN-119613346-A Method for preparing 5-bromopyrimidine 上海沃缨生物科技有限公司 2025-03-14 CN claimed
CN-119219648-A Preparation method of (1S) -1- (hydroxymethyl) -2-oxa-5-azabicyclo [2.2.1] heptane-5-carboxylic acid tert-butyl ester 浙江药领医药科技有限公司 2024-12-31 CN claimed
CN-118932196-A Method for separating rhenium and molybdenum by utilizing quaternary phosphonium salt modified material 武汉轻工大学 2024-11-12 CN claimed
CN-114835563-B Synthesis method of 4,4' -difluorobenzophenone 浙江中欣氟材股份有限公司 2024-04-26 CN claimed
CN-117024263-A Preparation method of 2,4, 6-trifluoro-benzoic acid 黑龙江立科新材料有限公司 2023-11-10 CN claimed
CN-116813529-A Synthesis method of 6-tert-butoxycarbonyl-2-amino-6-azaspiro [3.4] octane 安顺市人民医院 2023-09-29 CN claimed
CN-114425304-B Molecular sieve immobilized eutectic solvent material and preparation and application thereof 中国石油化工股份有限公司 2023-08-29 CN claimed
CN-115819362-A Efficient triallyl isocyanurate production process 北京华和拓科技开发有限责任公司 2023-03-21 CN claimed
WO-2007101769-A1 PROCESS FOR THE HYDROGENATION OF IMINES EVONIK DEGUSSA GMBH (DE) 2007-09-13 WO claimed
US-20070213540-A1 Process for the hydrogenation of imines DEGUSSA AG (DE) 2007-09-13 US claimed
EP-1663999-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES, LTD. (IN) 2006-06-07 EP claimed
US-20050075383-A1 Inhibitors of phophodiesterase type-IV RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 US claimed
WO-2005021515-A2 INHIBITORS OF PHOSPHODIESTERASE TYPE-IV RANBAXY LABORATORIES LIMITED (IN) 2005-03-10 WO claimed
US-5200516-A Synthesis of sugars from substituted and unsubstituted arene diols VIRGINIA TECH INTELLECTUAL PROPERTIES (US) 1993-04-06 US claimed
EP-0220118-B1 BICYCLIC NAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1992-01-02 EP claimed
EP-0297995-B1 POLYCYCLIC AROMATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND ANIMAL MEDICINE AND IN COSMETICS L'OREAL (FR) 1991-03-06 EP claimed
US-4826969-A SKIN AND EYE DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1989-05-02 US claimed
US-4283565-A REACTING A BENZYL HALIDE WITH A FORMATE, CONTACTING WITH AN ALCOHOL TO TRANSESTERIFY DYNAMIT NOBEL AG (DE) 1981-08-11 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213540-A1 Process for the hydrogenation of imines KCNH3, KCNH2, KMO KCNN4 256/4885ALDH1A1 1856/4885TSHR 2732/4885
US-20050075383-A1 Inhibitors of phophodiesterase type-IV PDE7A, PDE4A, PDE4B KCNN4 3329/4885ALDH1A1 718/4885TSHR 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.